Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Double-dummy, Randomised, Comparative, Multi-centre Phase III Study on the Efficacy and Tolerability of an 8-week Oral Treatment With 9 mg Budesonide Once Daily vs. 3 mg Budesonide Three-times Daily in Patients With Active Crohn's Disease

NCT01086553 is registered in ClinicalTrials.gov with Dr. Falk Pharma GmbH as lead sponsor.

NCT NCT01086553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01086553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Double-dummy, Randomised, Comparative, Multi-centre Phase III Study on the Efficacy and Tolerability of an 8-week Oral Treatment With 9 mg Budesonide Once Daily vs. 3 mg Budesonide Three-times Daily in Patients With Active Crohn's Disease
Lead sponsor
Dr. Falk Pharma GmbH
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2009
Completion date
December 31, 2012
Enrollment
471 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn´s disease